REPL

Replimune Group, Inc.

8.64 USD
-0.07 (-0.80%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Replimune Group, Inc. stock is up 9.51% since 30 days ago. The next earnings date is May 16, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 February’s closed higher than January.

About Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer.